Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Atara Biotherapeutics, Inc.
| (Name of Issuer) |
|
Common Stock, par value $0.0001 per share |
| (Title of Class of Securities) |
046513107 |
| (CUSIP Number) |
|
|
| December 31, 2020 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 046513107
|
SCHEDULE 13G/A
|
Page 2
of 8 Pages
|
|
1
|
NAME OF REPORTING PERSONS
BRIDGER MANAGEMENT, LLC
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) x
|
|
||
|
3
|
SEC USE ONLY
|
|||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
|||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
0
|
||
|
6
|
SHARED VOTING POWER
1,524,760
|
|||
|
7
|
SOLE DISPOSITIVE POWER
0
|
|||
|
8
|
SHARED DISPOSITIVE POWER
1,524,760
|
|||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|||
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
1.8% (1)
|
|||
|
12
|
TYPE OF REPORTING PERSON
IA
|
|||
(1) Based on 82,816,343 shares of common stock, par value $0.0001 per share (“Common Stock”), outstanding as of December 11, 2020, as the Issuer reported in its Form 8-K filed with the SEC on December 9, 2020.
|
CUSIP No. 046513107
|
SCHEDULE 13G/A
|
Page
3 of 8 Pages
|
|
1
|
NAME OF REPORTING PERSONS
ROBERTO MIGNONE
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) x
|
|
||
|
3
|
SEC USE ONLY
|
|||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
|||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
0
|
||
|
6
|
SHARED VOTING POWER
1,524,760
|
|||
|
7
|
SOLE DISPOSITIVE POWER
0
<
font style="font: 10pt times new roman">
|
|||
|
8
|
SHARED DISPOSITIVE POWER
1,524,760
|
|||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|||
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
1.8% (1)
|
|||
|
12
|
TYPE OF REPORTING PERSON
IN
|
|||
(1) Based on 82,816,343 shares of common stock, par value $0.0001 per share (“Common Stock”), outstanding as of December 11, 2020, as the Issuer reported in its Form 8-K filed with the SEC on December 9, 2020.
|
CUSIP
No. 046513107
|
SCHEDULE 13G/A
|
Page 4
of 8 Pages
|
| Item 1. | (a) Name of Issuer |
Atara Biotherapeutics, Inc.
| Item 1. | (b) Address of Issuer’s Principal Executive Offices |
611 Gateway Blvd., Suite 900
South San Francisco, CA 94080
| Item 2. | (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship: |
Bridger Management, LLC, a Delaware limited liability company, 90 Park Avenue – 40th Floor, New York, NY 10016
Mr. Roberto Mignone (“Mr. Mignone”), 90 Park Avenue – 40th Floor, New York, NY 10016. Mr. Mignone is a United States citizen.
| Item 2. | (d) Title of Class of Securities |
Common Stock, par value $0.0001 per share (the “Common Stock”)
| Item 2. | (e) CUSIP No.: |
046513107
| Item 3. | Not Applicable. |
|
CUSIP
No. 046513107
|
SCHEDULE 13G/A
|
Page
5 of 8 Pages
|
Item 4. Ownership
Information with respect to the Reporting Persons’ ownership of the Common Stock as of December 31, 2020, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Rep orting Person.
Bridger Healthcare, Ltd., Swiftcurrent Partners, L.P., and Swiftcurrent Offshore Master, Ltd. are the owners of record of the Common Stock reported herein. Bridger Management LLC is the investment adviser to Bridger Healthcare, Ltd., Swiftcurrent Partners, L.P., and Swiftcurrent Offshore Master, Ltd. Mr. Mignone is the manager of Bridger Management, LLC. Each of Bridger Management LLC and Mr. Mignone may be deemed to share beneficial ownership of the Common Stock reported herein.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
Item 6. Ownership of More Than Five Percent on Behalf of Another Person
See Item 4.
Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of Group
Not Applicable.
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
[Signature Page Follows:]
|
CUSIP No. 046513107
|
SCHEDULE 13G/A
|
Page
6 of 8 Pages
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DATED: February 16, 2021
| BRIDGER MANAGEMENT, LLC | |||
| By: | /s/ Roberto Mignone | ||
| Roberto Mignone, Manager | |||
| /s/ Roberto Mignone | |||
| Roberto Mignone, Individually | |||
|
CUSIP No. 046513107
|
SCHEDULE 13G/A
|
Page 7
of 8 Pages
|
EXHIBIT INDEX
Exhibit I: Joint Filing Statement Pursuant to Rule 13d-1(k)
|
CUSIP No. 046513107
|
SCHEDULE 13G/A
|
Page 8
of 8 Pages
|
Exhibit I
JOINT FILING STATEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
DATED: February 16, 2021
| BRIDGER MANAGEMENT, LLC | |||
| By: | /s/ Roberto Mignone | ||
| Roberto Mignone, Manager | |||
| /s/ Roberto Mignone | |||
| Roberto Mignone, Individually | |||